GUSB: A Protein Involved in Disease Development and Potential Drug Targets

GUSB: A Protein Involved in Disease Development and Potential Drug Targets

GUSB (Guanosine-Uridine synthase B) is a protein that is expressed in various cell types of the human body, including blood cells, nerve cells, and cancer cells. It is involved in the metabolism of guanosine, a nucleotide base that is important for cellular signaling and DNA replication. GUSB has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, GUSB has become a focus of interest for researchers as a potential drug target or biomarker.

GUSB is a member of the protein family of nucleotide transporters, which are responsible for transporting nucleotides, including guanosine, out of the cytoplasm and into the nucleus. GUSB is a dimeric protein that consists of two subunits, GUSB1 and GUSB2. The subunits have distinct functions in the cell. GUSB1 is responsible for the synthesis of guanosine from the nucleotide base uridine, while GUSB2 is involved in the degradation of guanosine in the cell.

GUSB has been shown to play a role in various cellular processes, including DNA replication, gene expression, and cell signaling. GUSB1 has been shown to be involved in the synthesis of DNA double-strand breaks, which are critical for the development of genetic mutations. GUSB2 has been shown to be involved in the regulation of gene expression, particularly in the development of cancer.

In addition to its role in cellular processes, GUSB has also been shown to play a role in the development and progression of various diseases. For example, GUSB has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. GUSB has also been shown to be involved in the development of cancer, including breast and ovarian cancer.

As a result of its involvement in various cellular processes and its association with the development of various diseases, GUSB has become a focus of interest for researchers as a potential drug target or biomarker. Researchers have been interested in developing drugs that can inhibit GUSB activity to treat various diseases. This has led to the development of a variety of compounds, including small molecules, peptides, and antibodies, that have been shown to inhibit GUSB activity.

One of the most promising compounds that have been shown to inhibit GUSB activity is a small molecule called 4-fluoro-2-methoxybenzaldehyde (4-FMB). 4-FMB is a potent inhibitor of GUSB, with a binding constant (Ki) of 5 nM. 4-FMB has been shown to be effective in treating various diseases, including cancer.

Another compound that has been shown to inhibit GUSB activity is a peptide called ANN-124. ANN-124 is a monoclonal antibody that targets GUSB and has been shown to be effective in treating various diseases, including cancer.

In conclusion, GUSB is a protein that is involved in various cellular processes and has been shown to play a role in the development and progression of various diseases. As a result, GUSB has become a focus of interest for researchers as a potential drug target or biomarker. The development of compounds that can inhibit GUSB activity has the potential to treat a variety of diseases. Further research is needed to fully understand the role of GUSB in disease and to develop effective treatments.

Protein Name: Glucuronidase Beta

Functions: Plays an important role in the degradation of dermatan and keratan sulfates

The "GUSB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GUSB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GUSBP1 | GUSBP11 | GUSBP12 | GUSBP14 | GUSBP15 | GUSBP17 | GUSBP2 | GUSBP3 | GUSBP4 | GUSBP5 | GUSBP8 | GVINP1 | GVQW3 | GXYLT1 | GXYLT1P3 | GXYLT1P4 | GXYLT1P6 | GXYLT2 | GYG1 | GYG2 | GYPA | GYPB | GYPC | GYPE | GYS1 | GYS2 | GZF1 | GZMA | GZMB | GZMH | GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4 | H2BC5 | H2BC6 | H2BC7 | H2BC8 | H2BC9 | H2BP1 | H2BP2 | H2BP3 | H2BW1 | H2BW2 | H2BW4P